Biomedical Sensors – Workshop II

Workshop II on Biomedical Sensors wil be held at 10:00-20:00 on November 2nd 2005, at the GSK Conference Centre, Oslo.
Av Rita Westvik, Seniorrådgiver

The Workshop is part of the MedCoast week/ScanBalt Forum 2005.

How will biomedical sensors shape the healthcare systems of the future? How can they impact the quality and cost of healthcare and what are the business opportunities in the Nordic region?

Challenges in healthcare are huge. The number of elderly people is increasing, with a corresponding rise in the use of healthcare resources. So-called welfare diseases are increasing. There is large potential in technologies that can give more cost-efficient services.

A Nordic consortium headed by SINTEF (Norway) and with the participants VTT (Finland), FOI (Sweden), S-SENCE (Sweden), STC (Denmark) and MedCoast-Scandinavia is conducting a foresight study FOBIS; Foresight Biomedical Sensors. The project is supported by the Nordic Innovation Centre. This workshop is the second in a series of four.

Workshop program

Registration and coffee

Welcome and objectives, Ingrid Svagård, SINTEF, project leader FOBIS

**Expert talks 10:15 – 13.00**

Ethical challenges in biosensor research and – applications Ole Johan Borge, Bioteknologinemnda

Potential of biomedical sensors; state of the art, future perspectives Erik Fosse, M.D., leader of the Interventional Centre, Rikshospitalet


Biomedical sensor technology: state-of the art and future roadmap Ralph Bernstein, Research Director, SINTEF ICT

Market issues/business opportunities Stein Lorentzen-Lund, CEO Alertis Medical AS

Lunch 13:00 – 13:45

Biomedical sensors in the pharmaceutical industry – “killer application”? Olav Flaten, Medical Director, GlaxoSmithKline AS

Panel discussion

Introduction to work groups

Work groups (between 5 and 10 in each group)

Presentations from work groups in plenum Concluding remarks

Scanbalt Conference Opening Event: we order maxi-taxies and leave GSK to join this event: see next page for more information.

20:00 End

How to register?

Register online at later than 28 October.

Contact person: Ingrid Svagård, SINTEF,, phone: +47-7355 0442.


The workshop target group is participants from a cross-section of the health care and technology sector representing the following areas:

Patients, private users, home care
Manufacturers of diagnostic equipment
Doctors office (practicing MDs)
Vendors of communication services
Knowledge centers (Universities, research
Security and bio-defense institutions and consultants)
Drug discovery and development

Take part in the workshop to be inspired, to learn the new possibilities, to influence the future, to be the cutting edge and to catch new business opportunities!


The workshop will be held at GSK Conference Centre, Forskningsveien 2a in Oslo.

The Conference Centre is located north of the city centre in the heart of Oslos’ bio-medicine cluster, the Gaustabekk Valley, close to the SINTEF facilities in Oslo.

The location is easy to reach by bus, tram or suburban railway, from Jernbanetorget and the bus terminal which are central junctions for train connections, the airport train, and other means of transport. We recommend you to choose public transportation or taxi as parking facilities are limited.

Please see for assistance.

Scanbalt Conference Opening Event!

We will join in on the ScanBalt Opening Event at AstraZeneca facilitites in Hoffsveien 2, from 18.30 till 20.00. There will be live music, finger-food and an expert panel debate.

The topic for the debate is : Premises for Life Science research and commercialization of new ideas. Visit learn more about this conference.

Tentative panel lists: Professor Ole Petter Ottersen, Universitetet i Oslo Professor Arvid Carlsson, Carlsson research Center, Gøteborg Univ. Winner of Nobel laurate 2000 in Medicine Professor John Glomset, University of Washington Professor Leena Peltonen, Helsinki University, leader of Nordic centre of Excellence within Biobanks Dr. med Henrik Lund, global vice president Clinical development, AstraZeneca PLC.